Reactive oxygen species and lung tumorigenesis by mutant K-ras: A working hypothesis

Experimental Lung Research

Volumn 31, Issue 1, 2005, Pages 83-104

  Maciag, Anna ^a   Anderson, Lucy M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cyclooxygenase; K ras mutant; Lung tumor; Reactive oxygen

Indexed keywords

5 (4 FLUOROPHENYL) 1 [(4 METHYLSULFONYL)PHENYL] 3 TRIFLUOROMETHYLPYRAZOLE; CATALASE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; MUTANT PROTEIN; PEROXIDE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; COMET ASSAY; CONFERENCE PAPER; DELETION MUTANT; DNA DAMAGE; ENZYME INDUCTION; ENZYME RELEASE; GENETIC TRANSFECTION; LUNG ALVEOLUS EPITHELIUM; LUNG CANCER; LUNG CARCINOGENESIS; MOUSE; NONHUMAN; ONCOGENE; ONCOGENE K RAS; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; ANIMALS; CYCLOOXYGENASE 2; DNA DAMAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, RAS; HUMANS; LUNG NEOPLASMS; MEMBRANE PROTEINS; MUTATION; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; REACTIVE OXYGEN SPECIES;

EID: 11144219953     PISSN: 01902148     EISSN: None     Source Type: Journal    
DOI: 10.1080/01902140490495048     Document Type: Conference Paper

References (127)

1. Bos JL: Ras oncogenes in human cancer: a review. Cancer Res. 1989;49:4682-4689.
2. Minamoto T, Mai M, Ronai Z: K-ras mutation: early detection in molecular diagnosis and risk assessment of colorectal, pancreas, and lung cancers-a review. Cancer Detect Prevent. 2000;24:1-12.
3. Malkinson AM: Primary lung tumors in mice as an aid for understanding, preventing, and treating human adenocarcinoma of the lung. Lung Cancer. 2001;32:265-279.
4. Westra WH, Baas IO, Hruban RH, Askin FB, Wilson K, Offerhaus GJA, Slebos RJC: K-ras oncogene activation in atypical alveolar hyperplasias of the human lung. Cancer Res. 1996;56:2224-2228.
5. Kitamura H, Kameda Y, Ito T, Hayashi H: Atypical adenomatous hyperplasia of the lung. Implications for the pathogenesis of peripheral lung adenocarcinoma. Am J Clin Pathol. 1999;111:610-622.
6. Belinsky SA, Devereux TR, Foley JF, Maronpot RR, Anderson MW: Role of the alveolar type II cell in the development and progression of pulmonary tumors induced by 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone in the A/J mouse. Cancer Res. 1992;52:3164-3173.
7. Kawano R, Nishisaka T, Takeshima Y, Yonehara S, Inai K: Role of point mutation of the K-ras gene in tumorigenesis of B6C3F1 mouse lung lesions induced by urethane. Jpn J Cancer Res. 1995;86:802-810.
8. Kawano R, Takeshima Y, Inai K: Effects of K-ras gene mutation in the development of lung lesions induced by 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)- 1-butanone in A/J mice. Jpn J Cancer Res. 1996;87:44-50.
9. Maher J, Baker DA, Manning M, Dibb NJ, Roberts IA: Evidence for cell-specific differences in transformation by N-, H-, and K-ras. Oncogene. 1995;11:1639-1647.
10. Lohr M, Muller P, Zauner I, Schmidt C, Trautmann B, Thevenod F, Capella G, Farre A, Liebe S, Jesnowski R: Immortalized bovine pancreatic duct cells become tumorigenic after transfection with mutant k-ras. Virchows Arch. 2001;438:581-590.
11. Zhang Z, Wang Y, Vikis HG, Johnson L, Liu G, Li J, Anderson MW, Sills RC, Hong HL, Devereux TR, Jacks T, Guan KL, You M: Wildtype Kras2 can inhibit lung carcinogenesis in mice. Nat Gen. 2001;29:25-33.
12. Thrane EV, Becher R, Lag M, Refsnes M, Huitfeldt HS, Schwarze PE: Differential distribution and increased levels of ras proteins during lung development. Exp Lung Res. 1997;23:35-49.
13. Sithanandam G, Ramakrishna G, Diwan BA, Anderson LM: Selective mutation of K-ras by N-ethylnitrosourea shifts from codon 12 to codon 61 during fetal mouse lung maturation. Oncogene. 1998;17:493-502.
14. Kammouni W, Ramakrishna G, Sithanandam G, Smith GT, Fornwald LW, Masuda A, Takahashi T, Anderson LM: Increased K-ras protein and activity in mouse and human lung epithelial cells at confluence. Cell Growth Diff. 2002;13:441-448.
15. Hegi ME, Devereux TR, Dietrich WF, Cochran CJ, Lander ES, Foley JF, Maronpot RR, Anderson MW, Wiseman RW: Allelotype analysis of mouse lung carcinomas reveals frequent allelic losses on chromosome 4 and an association between allelic imbalances on chromosome 6 and K-ras activation. Cancer Res. 1994;54:6257-6264.
16. Ramakrishna G, Perella C, Birely L, Diwan BA, Fornwald LW, Anderson LM: Decrease in K-ras p21 and increase in Rafl and activated Erk1 and 2 in mouse lung tumors initiated by N-nitrosodimethylamine and promoted by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Toxicol Appl Pharmacol. 2002;179:21-34.
17. Li J, Zhang Z, Dai Z, Plass C, Morrison C, Wang Y, Wiest JS, Anderson MW, You M: LOH of chromosome 12p correlates with Kras2 mutation in non-small cell lung cancer. Oncogene. 2003;22:1243-1246.
18. Thompson TA, Haag JD, Lindstrom MJ, Griep AE, Lohse JK, Gould MN: Decreased susceptibility to NMU-induced mammary carcinogenesis in transgenic rats carrying multiple copies of a rat ras gene driven by the rat Harvey ras promoter. Oncogene. 2002;21:2797-2804.
19. Diaz R, Ahn D, Lopez-Barcons L, Malumbres M, Perez de Castro I, Lue J, Ferrer-Miralles N, Mangues R, Tsong JH, Garcia R, Perez-Soler R, Pellicer A: The N-ras protooncogene can suppress the malignant phenotype in the presence or absence of its oncogene. Cancer Res. 2002;62:4514-4518.
20. Johnson L, Mercer K, Greenbaum D, Bronson RT, Crowley D, Tuveson DA, Jacks T: Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature. 2001;410:1111-1116.
21. Jackson EL, Willis N, Mercer K, Bronson RT, Crowley D, Montoya R, Jacks T, Tuveson DA: Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 2001;15:3243-3248.
22. Meuwissen R, Linn SC, van der Valk M, Mooi WJ, Berns A: Mouse model for lung tumorigenesis through Cre controlled sporadic activation of the K-ras oncogene. Oncogene. 2001;20:6551-6558.
23. Guerra C, Mijimolle N, Dhawahir A, Dubus P, Barradas M, Serrano M, Compuzano V, Barbacid M: Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell. 2003;4:111-120.
24. Fisher GH, Wellen SL, Klimstra D, Lenczowski JM, Tichelaar JW, Lizak MJ, Whitsett JA, Koretsky A, Varmus HE: Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev. 2001;15:3249-3262.
25. Floyd HS, Tichelaar JW, Dance ST, Everitt J, Whitsett JA, Miller MS: Expression of mutant human KI-ras induced lung tumors in bitransgenic mice. Toxicologist. 2003;72:85.
26. Sundaresan M, Yu ZX, Ferrans VJ, Sulciner DJ, Gutkind JS, Irani K, Goldschmidt-Clermont PJ: Finkel T: Regulation of reactive-oxygen-species generation in fibroblasts by Racl. Biochem J. 1996;318:379-382.
27. Irani K, Xia Y, Zweier JL, Sollot SJ, Der CJ, Fearon ER, Sundaresan M, Finkel T, Goldschmidt-Clermont PJ: Mitogenic signaling mediated by oxidants in Ras-transformed fibroblasts. Science. 1997;275:1649-1652.
28. Liou JS, Chen Y, Chen JS, Faller DV: Oncogenic ras mediates apoptosis in response to protein kinase C inhibition through the generation of reactive oxygen species. J Biol Chem. 2000;275:39001-39011.
29. Cho HJ, Jeong HG, Lee JS, Woo ER, Hyun JW, Chung MH, You HJ: Oncogenic H-ras enhances DNA repair through the ras/phosphatidylinositol 3-kinase/Racl pathway in NIH3T3 cells. Evidence for association with reactive oxygen species. J Biol Chem. 2002;277:19358-19366.
30. Walsh AB, Bar-Sagi D: Differential activation of the Rac pathway by Ha-ras and K-ras. J Biol Chem. 2001;276:15609-15615.
31. Liu R, Li B, Qui M: Elevated Superoxide production by active H-ras enhances human lung WI-38VA-13 cell proliferation, migration and resistance to TNF-α. Oncogene. 2001;20:1486-1496.
32. Santillo M, Mondola P, Seru R, Annella T, Cassano S, Ciullo I, Tecce MF, Iacomino G, Damiano S, Cuda G, Paterno R, Martignetti V, Mele E, Feliciello A, Awedimento EV: Opposing functions of Ki and Ha-ras genes in the regulation of redox signals. Curr Biol. 2001;11:614-619.
33. Lee AC, Fenster BE, Ito H, Takeda K, Bae NS, Hirai T, Yu ZX, Ferrans VJ, Howard BH, Finkel T: Ras proteins induce senescence by altering the intracellular levels of reactive oxygen species. J Biol Chem. 1999;274:7936-7940.
34. Thannickal VJ, Day RM, Klinz SG, Bastien MC, Larios JM, Fanburg BL: Ras-dependent and independent regulation of reactive oxygen species by mitogenic growth factors and TGF-β1. FASEB J. 2000;14:1741-1748.
35. Yang JQ, Li S, Domann FE, Buettner GR, Oberley LW: Superoxide generation in v-Ha-ros-transfected human keratinocyte HaCaT cells. Mol Carcinogen. 1999;26:180-188.
36. Yang JQ, Li S, Huang Y, Zhang HJ, Domann FE, Buettner GR, Oberley LW: V-Ha-ras overexpression induces Superoxide production and alters levels of primary antioxidant enzymes. Antioxid Redox Signal. 2001;3:697-709.
37. Maciag AE, Sithanandam G, Kasprzak KS, Anderson LM: Expression of mutant K-rasV12 in mouse lung epithelial cells increases generation of peroxides through COX-2, resulting in DNA damage. Toxicologist. 2003;72:235.
38. v12 increases COX-2, peroxides, and DNA damage in lung cells. Carcinogenesis. 2004;25:1-7.
39. Reitz DB, Li JJ, Norton MB, Reinhard EJ, Collins JT, Anderson GD, Gregory SA, Koboldt CM, Perkins WE, Seibert K, Isakson PC: Selective cyclooxygenase inhibitors: novel 1,2-diarylcyclopentenes are potent and orally active COX-2 inhibitors. J Med Chem. 1994;37:3878-3881.
40. Sheng GG, Shao J, Sheng H, Hooton EB, Isakson PC, Morrow JD, Coffey RJ, DuBois RN, Beauchamp RD: A selective cyclooxygenase 2 inhibitor suppresses the growth of H-ras-transformed rat intestinal epithelial cells. Gastroenterology. 1997;113:1883-1891.
41. Sheng H, Williams CS, Shao J, Liang P, DuBois RN, Beauchamp RD: Induction of cyclooxygenase-2 by activated Ha-ras oncogene in Rat-1 fibroblasts and the role of mitogen-activated protein kinase pathway. J Biol Chem. 1998;273:22120-22127.
42. Sheng H, Shao J, Dixon DA, Williams CS, Prescott SM, DuBois RN, Beauchamp RD: Transforming growth factor-B1 enhances Ha-ras-induced expression of cyclooxygenase-2 in intestinal epithelial cells via stabilization of mRNA. J Biol Chem. 2000;275:6628-6635.
43. Sheng H, Shao J, DuBois RN: K-ras-mediated increase in cyclooxygenase 2 mRNA stability involves activation of the protein kinase B1. Cancer Res. 2001;61:2670-2675.
44. Araki Y, Okamura S, Hussain SP, Nagashima M, He P, Shiseki M, Miura K, Harris CC: Regulation of cyclooxygenase-2 expression by the Wnt and Ras pathways. Cancer Res. 2003;63:728-734.
45. Heasley LE, Thaler S, Nicks M, Price B, Skorecki K, Nemenoff RA: Induction of cytosolic phospholipase A2 by oncogenic Ras in human non-small cell lung cancer. J Biol Chem. 1997;272:14501-14504.
46. Nikolic D, van Breemen RB: DNA oxidation induced by cyclooxygenase-2. Chem Res Toxicol. 2001;14:351-354.
47. Lin S Y, Tsai SJ, Wang LH, Wu MF, Lee H: Protection by quercetin against cooking oil fumes-induced DNA damage in human lung adenocarcinoma CL-3 cells: role of COX-2. Nutr Cancer. 2002;44:95-101.
48. Morita I, Schindler M, Regier MK, Otto JC, Hori T, DeWitt DL, Smith WL: Different intracellular locations for prostaglandin endoperoxide H synthase-1 and -2. J Biol Chem. 1995;270:10902-10908.
49. Williams CS, Mann M, DuBois RN: The role of cyclooxygenases in inflammation, cancer, and development. Oncogene. 1999;18:7908-7916.
50. Cao Y, Prescott SM: Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J Cell Physiol. 2002;190:279-286.
51. Wolff H, Saukkonen K, Anttila S, Karjalainen A, Vainio H, Ristimaki A: Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res. 1998;58:4997-5001.
52. Hida T, Yatabe Y, Achiwa H, Muramatsu H, Kozaki K, Nakamura S, Ogawa M, Mitsudomi T, Sugiura T, Takahashi T: Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res. 1998;58:3761-3764.
53. Ochiai M, Oguri T, Isobe T, Ishioka S, Yamakido M: Cyclooxygenase-2 (COX-2) mRNA expression levels in normal lung tissues and non-small cell lung cancers. Jpn J Cancer Res. 1999;90:1338-1343.
54. Watkins DN, Lenzo JC, Segal A, Garlepp MJ, Thompson PJ: Expression and localization of cyclooxygenase isoforms in non-small cell lung cancer. Eur Respir J. 1999;14:412-418.
55. Hosomi Y, Yokose T, Hirose Y, Nakajima R, Nagai K, Nishiwaki Y, Ochiai A: Increased cycloxygenase 2 (COX-2) expression occurs frequently in precursor lesions of human adenocarcinoma of the lung. Lung Cancer. 2000;30:73-81.
56. Yoshimatsu K, Altorki NK, Golijanin D, Zhang F, Jakobsson PJ, Dannenberg AJ, Subbaramaiah K: Inducible prostaglandin E synthase is overexpressed in non-small cell lung cancer. Clin Cancer Res. 2001;7:2669-2674.
57. Sweeney CJ, Marshall MS, Barnard DS, Heilman DK, Billings SD, Cheng L, Marshall SJ, Yip-Schneider MT: Cyclooxygenase-2 expression in primary cancers of the lung and bladder compared to normal adjacent tissue. Cancer Detect Prev. 2002;26:238-244.
58. Hasturk S, Kemp B, Kalapurakal SK, Kurie JM, Hong WK, Lee JS: Expression of cyclooxygenase-1 and cyclooxygenase-2 in bronchial epithelium and nonsmall cell lung carcinoma. Cancer. 2002;94:1023-1031.
59. Ermert L, Dierkes C, Ermert M: Immunohistochemical expression of cyclooxygenase isoenzymes and downstream enzymes in human lung tumors. Clin Cancer Res. 2003;9:1604-1610.
60. Fang HY, Lin TS, Lin JP, Wu YC, Chow KC, Wang LS: Cyclooxygenase-2 in human non-small cell lung cancer. Eur J Surg Oncol. 2003;29:171-177.
61. Achiwa H, Yatabe Y, Hida T, Kuroishi T, Kozaki K, Nakamura S, Ogawa M, Sugiura T, Mitsudomi T, Takahashi T: Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin Cancer Res. 1999;5:1001-1005.
62. Khuri FR, Wu H, Lee JJ, Kemp BL, Lotan R, Lippman SM, Feng L, Hong WK, Xu XC: Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage 1 non-small cell lung cancer. Clin Cancer Res. 2001;7:861-867.
63. Brabender J, Park J, Metzger R, Schneider PM, Lord RV, Holscher AH, Danenberg KD, Danenberg PV: Prognostic significance of cyclooxygenase 2 mRNA expression in non-small cell lung cancer. Ann Surg. 2002;235:440-443.
64. Campa D, Zienolddiny S, Maggini V, Skaug V, Haugen A, Canzian F: Association of a common polymorphism in the cyclooxygenase 2 gene with risk of non-small cell lung cancer. Carcinogenesis. 2003;25:229-235.
65. Hida T, Kozaki K, Muramatsu H, Masuda A, Shimizu S, Mitsudomi T, Sugiura T, Ogawa M, Takahashi T: Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin Cancer Res. 2000;6:2006-2011.
66. Altorki NK, Keresztes RS, Port JL, Libby DM, Korst RJ, Flieder DB, Ferrara CA, Yankelevitz DF, Subbaramaiah K, Pasmantier MW, Dannenberg AJ: Celecoxib, a selective cyclooxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. J Clin Oncol. 2003;21:2645-2650.
67. El-Bayoumy K, Iatropoulos M, Amin S, Hoffmann D, Wynder EL: Increased expression of cyclooxygenase-2 in rat lung tumors induced by the tobacco-specific nitrosamine 4-(methylnitrosamino)-4-(3-pyridyl)-1-butanone: the impact of a high fat diet. Cancer Res. 1999;59:1400-1403.
68. Kitayama W, Denda A, Yoshida J, Sasaki Y, Takahama M, Murakawa K, Tsujiuchi T, Tsutsumi M, Konishi Y: Increased expression of cyclooxygenase-2 protein in rat lung tumors induced by N-nitrosobis(2-hydroxypropyl)amine. Cancer Lett. 2000;148:145-152.
69. Li H, Chen F, Yu L, Liu M, Chen H, Zhang Y, Liu X: Expression of inflammation related enzymes during experimental rat lung Carcinogenesis. Zhonghua Zhong Liu Za Ahi. 2002;24:316-319.
70. Gottschling BC, Maronpot RR, Hailey JF, Peddada S, Moomaw CR, Klaunig JE, Nyska A: The role of oxidative stress in indium phosphide-induced lung Carcinogenesis in rats. Toxicol Sci. 2001;64:28-40.
71. Rioux N, Castonguay A: Prevention of NNK-induced lung tumorigenesis in A/J mice by acetylsalicylic acid and NS-398. Cancer Res. 1998;58:5354-5360.
72. Yao R, Rioux N, Castonguay A, You M: Inhibition of COX-2 and induction of apoptosis: two determinants of nonsteroidal anti-inflammatory drugs' chemopreventive efficacies in mouse lung tumorigenesis. Exp Lung Res. 2000;26:731-742.
73. Wardlaw SA, March TH, Belinsky SA: Cyclooxygenase-2 expression is abundant in alveolar type II cells in lung cancer-sensitive mouse strains and in premalignant lesions. Carcinogenesis. 2000;21:1371-1377.
74. Bauer AK, Dwyer-Nield LD, Malkinson AM: High cyclooxygenase 1 (COX-1) and cyclooxygenase 2 (COX-2) contents in mouse lung tumors. Carcinogenesis. 2000;21:543-550.
75. Moody TW, Leyton J, Zakowicz H, Hida T, Kang Y, Jakowlew S, You L, Ozbun L, Zia H, Youngberg J, Malkinson A: Indomethacin reduces lung adenoma number in A/J mice. Anticancer Res. 2001;21(3B):1749-1755.
76. Bauer AK, Dwyer-Nield LD, Hankin JA, Murphy RC, Malkinson AM: The lung tumor promoter, butylated hydroxytoluene (BHT), causes chronic inflammation in promotion-sensitive BALB/cBYJ mice but not in promotion-resistant CXB4 mice. Toxicology. 2001;169:1-15.
77. Kisley LR, Barrett BS, Dwyer-Nield LD, Bauer AK, Thompson DC, Malkinson AM: Celecoxib reduces pulmonary inflammation but not lung tumorigenesis in mice. Carcinogenesis. 2002;23:1653-1660.
78. Collins AR: Oxidative DNA damage, antioxidants, and cancer. BioEssays. 1999;21:238-246.
79. Phillips DH: Smoking-related DNA and protein adducts in human tissues. Carcinogenesis. 2002;23:1979-2004.
80. Asami S, Manabe H, Miyake J, Tsurudome Y, Hirano T, Yamaguchi R, Itoh H, Kasai H: Cigarette smoking induces an increase in oxidative DNA damage, 8-hydroxydeoxyguanosine, in a central site of the human lung. Carcinogenesis. 1997;18:1763-1766.
81. Rodin SN, Rodin AS: On the origin of p53 G:C to T:A transversions in lung cancers. Mutat Res. 2002;508:1-19.
82. Inoue M, Osaki T, Noguchi M, Hirohashi S, Yasumoto K, Kasai H: Lung cancer patients have increased 8-hydroxydeoxyguanosine levels in peripheral lung tissue DNA. Jpn J Cancer Res. 1998;89:691-695.
83. Iizuka S, Taniguchi N, Makita A: Enzyme-linked immunosorbent asay for human manganese-containing superoxide dismutase and its content in lung tissue. J Natl Cancer Inst. 1984;72:1043-1049.
84. Jiang CG: Manganese-containing superoxide dismutase activity in human lung cancer tissue. Zhonghua Zhong Liu Za Zhi. 1990;12:348-350.
85. Iwasaki M, Ogawa J, Inoue H, Kijima H, Watanabe K: Immunohistochemical properties of lipid peroxidation and prognosis in adenocarcinoma of the lung. J Cardiovasc Surg (Torino). 1998;39:233-236.
86. Chung-man HJ, Zheng S, Comhair SA, Farver C, Erzurum SC: Differential expression of manganese superoxide dismutase and catalase in lung cancer. Cancer Res. 2001;61:8578-8585.
87. Guner G, Islekel H, Oto G, Hazan E, Acikel U: Evaluation of some antioxidant enzymes in lung carcinoma tissue. Cancer Lett. 1996;103:233-239.
88. Korotkina RN, Matskevich GN, Devlikanova AS, Vishnevskii AA, Kunitsyn AG, Karelin AA: Activity of glutathione-metabolizing and antioxidant enzymes in malignant and benign tumors of human lungs. Bull Exp Biol Med. 2002;133:606-608.
89. Zieba M, Suwalski M, Kwiatkowska S, Piasecka G, Grzelewska-Rzymowska I, Stolarek R, Nowak D: Comparison of hydrogen peroxide generation and the content of lipid peroxidation products in lung cancer tissue and pulmonary parenchyma. Respir Med. 2000;94:800-805.
90. Chen H, Lum A, Seifried A, Wilkens LR, Le Marchand L: Association of the NAD(P)H:quinone oxidoreductase 609C to T polymorphism with a decreased lung cancer risk. Cancer Res. 1999;59:3045-3048.
91. Lin P, Wang HJ, Lee H, Lee HS, Wang SL, Hsueh YM, Tsai KJ, Chen CY: NAD(P)H:quinone oxidoreductase polymorphism and lung cancer in Taiwan. J Toxicol Environ Health A. 1999;58:187-197.
92. Hamajima N, Matsuo K, Iwata H, Shinoda M, Yamamura Y, Kato T, Hatooka S, Mitsudomi T, Suyama M, Kagam Y, Ogura M, Ando M, Sugimura Y, Tajima K: NAD(P)H:quinone oxidoreductase 1 (NQO1) C609T polymorphism and the risk of eight cancers for Japanese. Int J Clin Oncol. 2002;7:103-108.
93. Lin P, Hsueh YM, Ko JL, Liang YF, Tsai KJ, Chen CY: Analysis of NQO1, GSTP1, and MnSOD polymorphisms on lung cancer risk in Taiwan. Lung Cancer. 2003;40:123-129.
94. Wang LI, Miller DP, Sai Y, Liu G, Su L, Wain JC, Lynch TJ, Christiani DC: Manganese superoxide dismutase alanine-to-valine polymorphism at codon 16 and lung cancer risk. J Natl Cancer Inst 2001;93:1818-1821.
95. Le Marchand L, Donlon T, Lum-Jones A, Seifried A, Wilkens LR: Association of the hOGG1 Ser326Cys polymorphism with lung cancer risk. Cancer Epidemiol Biomarkers Prev. 2002;11:409-412.
96. Wikman H, Risch A, Klimek F, Schmezer P, Spiegelhalder B, Dienemann H, Kayser K, Schulz V, Drings P, Bartsch H: nOGG1 polymorphism and loss of heterozygosity (LOH): significance for lung cancer susceptibility in a causasian populaiton. Int J Cancer. 2000;88:932-937.
97. Ito H, Hamajima N, Takezaki T, Matuso K, Tajima K, Hatooka S, Misudomi T, Suyama S, Sato S, Ueda R: A limited association of OGG1 Ser326Cys polymorphism for adenocarcinoma of the lung. J Epidemiol. 2002;12:258-265.
98. Al-Tassan N, Eisen T, Maynard J, Bridle H, Shah B, Fleischmann C, Sampson JR, Cheadle JP, Houlston RS: Inherited variants of MYH are unlikely to contribute to the risk of lung carcinoma. Hum Genet. 2004;114:207-210.
99. Riboli E, Norat T: Epidemiological evidence of the protective effect of fruits and vegetables on cancer risk. Am J Clin Nutr. 2003;78(Suppl 3):559S-569S.
100. Miller AB, Altenburg HP, Bueno-De-Mesquita B, Boshuizen HC, Agudo A, Berrino F, Gram IT, Janson L, Linseisen J, Overvad K, Rasmuson T, Vineis P, Lukanova A, Allen N, Amiano P, Barricarte A, Berglund G, Boeing H, Clavel-Chapelon F, Day NE, Hallmans G, Lund E, Martinez C, Navarro C, Palli D, Panico S, Peeters PH, Quiros JR, Tjonneland A, Tumino R, Trichopoulou A, Trichopoulos D, Slimani N, Riboli E: Fruits and vegetables and lung cancer: Findings from the European prospective investigation into cancer and nutrition. Int J Cancer. 2004;108:269-276.
101. Cohen V, Khuri FR: Progress in lung cancer chemoprevention. Cancer Control. 2003;10:315-324.
102. Schreinemachers DM, Everson RB: Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology. 1994;5:138-146.
103. Harris RE, Beebe-Donk J, Schuller HM: Chemoprevention of lung cancer by non-steroidal antiinflammatory drugs among cigarette smokers. Oncol Rep. 2002;9:693-695.
104. Akhmedkhanov A, Toniolo P, Zeleniuch-Jacquotte A, Koenig KL, Shore RE: Aspirin and lung cancer in women. Br J Cancer. 2002;87:49-53.
105. Moysich KB, Menezes RJ, Ronsani A, Swede H, Reid ME, Cummings KM, Falkner KL, Loewen GM, Bepler G: Regular, aspirin use and lung cancer risk. BMC Cancer. 2002;2:31.
106. Muscat JE, Chen SQ, Richie JP, Altorki NK, Citron M, Oslon S, Neugut AI, Stellman SD: Risk of lung carcinoma among users of nonsteroidal antiinflammatory drugs. Cancer. 2003;97:1732-1736.
107. Holick CN, Michaud DS, Leitzmann MF, Willett WC, Giovannucci E: Aspirin use and lung cancer in men. Br J Cancer. 2003;89:1705-1708.
108. Hassett C, Mustafa MG, Coulson WF, Elashoff RM: Murine lung carcinogenesis following exposure to ambient ozone concentrations. J Natl Cancer Inst. 1985;75:771-777.
109. Last JA, Warren DL, Pecqut-Goad E, Witschi H: Modification by ozone of lung tumor development in mice. J Natl Cancer Inst. 1987;78:149-154.
110. Boorman GA, Hailey R, Grumbein S, Cous BJ, Herbert RA, Goehl T, Mellick PW, Roycroft JH, Haseman JK, Sills R: Toxicology and carcinogenesis studies of ozone and ozone/4-(N-nitrosomethyl-amino)-1-(3-pyridyl)-1-butanone in Fischer-344/N rats. Toxicol Pathol. 1994;22:545-554.
111. Boorman GA, Sills RC, Grumbein S, Hailey R, Miller RA, Herbert RA: Long-term toxicity studies of ozone in F344/N rats and B6C3F1 mice. Toxicol Lett. 1995;82-83:301-306.
112. Herbert RA, Hailey JR, Brumbein S, Chou BJ, Sills RC, Haseman JK, Goehl T, Miller RA, Roycroft JH, Boorman GA: Two-year and lifetime toxicity and carcinogenicity studies of ozone in B6C3F1 mice. Toxicol Pathol. 1996;24:539-548.
113. Sills RC, Hong HL, Greenwell A, Herbert RA, Boorman GA, Devereux TR: Increased frequency of K-ras mutations in lung neoplasms from female B6C3F1 mice exposed to ozone for 24 or 30 months. Carcinogenesis. 1995;16:1623-1628.
114. Sakumi K, Tominaga Y, Furuichi M, Xu P, Tsuzuki T, Sekiguchi M, Nakabeppu Y: Ogg1 knockout-associated lung tumorigenesis and its suppression by Mth1 gene disruption. Cancer Res. 2003;63:902-905.
115. Tsuzuki T, Egashira A, Igarashi H, Iwakuma T, Nakatsuru Y, Tominaga Y, Kawate H, Nakao K, Nakamura K, Ide F, Kura S, Nakabeppu Y, Katsuki M, Ishikawa T, Sekiguchi M: Spontaneous tumorigenesis in mice defective in the MTH1 gene encoding 8-oxo-dGTPase. Proc Natl Acad Sci U S A. 2001;98:11456-11461.
116. Minowa O, Arai T, Hirano M, Monden Y, Nakai S, Fukuda M, Itoh M, Takano H, Hippou Y, Aburatani H, Masumura K, Nohmi T, Nishimura S, Noda T: Mmh/Ogg1 gene inactivation results in accumulation of 8-hydroxyguanine in mice. Proc Natl Acad Sci U S A. 2000;97:4156-4161.
117. Ichinose T, Yajima Y, Nagashima M, Takenoshita S, Nagamachi Y, Sagai M: Lung carcinogenesis and formation of 8-hydroxy-deoxyguanosine in mice by diesel exhaust particles. Carcinogenesis. 1997;18:185-192.
118. Risom L, Dybdahl M, Boronholdt J, Vogel U, Wallin H, Moller P, Loft S: Oxidative DNA damage and defence gene expression in the mouse lung after short-term exposure to diesel exhaust particles by inhalation. Carcinogenesis. 2003;24:1847-1852.
119. Maehira F, Miyagi I, Asato T, Eguchi T, Takei H, Nakatsuki K, Fukuoka M, Zaha F: Alterations of protein kinase C, 8-hydroxydeoxyguanosine, and K-ras oncogene in rat lungs exposed to passive smoking. Clin Chim Acta. 1999;289:133-144.
120. Tsurudome Y, Hirano T, Yamato H, Tanaka I, Sagai M, Hirano H, Nagata N, Itoh H, Kasai H: Changes in levels of 8-hydroxyguanine in DNA, its repair and OGG1 mRNA in rat lungs after intratracheal administration of diesel exhaust particles. Carcinogenesis. 1999;20:1573-1576.
121. Chung FL, Kellof G, Steele V, Pittman B, Zang E, Jiao D, Rigotty J, Choi CI, Rivenson A: Chemopreventive efficacy of arylalkyl isothiocyanates and N-acetylcysteine for lung tumorigenesis in Fischer rats. Cancer Res. 1996;56:772-778.
122. Hecht SS: Chemoprevention of lung cancer by isothiocyanates. Adv Exp Med Biol. 1996;401:1-11.
123. Hecht SS: Approaches to Chemoprevention of lung cancer based on carcinogens in tobacco smoke. Environ Health Perspect. 1997;105 (Suppl 4):955-964.
124. You M, Bergman G: Preclinical and clinical models of lung cancer Chemoprevention. Hematol Oncol Clin North Am. 1998;12:1037-1053.
125. Chung EL: Chemoprevention of lung cancer by isothiocyanates and their conjugates in A/J mouse. Exp Lung Res. 2001;27:319-330.
126. Cohen LA: A review of animal model studies of tomato carotenoids, lycopene, and cancer chemoprevention. Exp Biol Med. 2002;227:864-868.
127. Singh NP, McCoy MT, Tice RR, Schneider EL: A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res. 1988;175:184-191.